- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pending - - Creates strong synergies by combining ...
- Topline clinical data readouts expected in late Q3 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004 - CYB003: A proprietary deuterated psilocybin analog for the ...
Good morning, and thank you for joining the Cybin Second Quarter 2026 Financial Results and Corporate Update Call. As a reminder, our press release detailing today's updates is available in the ...
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (CYBN) (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental ...
Through its wholly-owned subsidiary, Cybin IRL Limited, Canadian-based psychedelics biotech Cybin Inc. CYBN signed an agreement with next-gen psychedelics producer Mindset Pharma Inc. MSSTF for an ...
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands ...
Investors might want to bet on Cybin Inc. , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices - ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results